Frontlight ResearchEarly access
Lung cancer trials in United Kingdom
152 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in United KingdomA Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
- Where
- Leicester, London, Metropolitan Borough of Wirral
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07871214 - No phaseTaking peopleEuropean Real-World Registry for Use of the Ion Endoluminal System
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT06923774 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton, Sutton
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 2Taking peopleA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Where
- Barnet, London, Manchester, Nottingham
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05967689 - Phase 1/2Active, not recruitingA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Where
- Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 327 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00 - Phase 1/2Taking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Glasgow, Scotland, London, Newcastle upon Tyne
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Cambridge, Glasgow, Scotland, London, Sutton
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 2/3Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- London, Newcastle upon Tyne
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Cambridge, London, Middlesex
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 1/2Taking peopleHTL0039732 in Participants With Advanced Solid Tumours
- Where
- Cambridge, Cardiff, Dundee, Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 150
- Run by
- Cancer Research UK
See details and how to joinNCT05944237 - Phase 3Taking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - Phase 3Taking peopleApixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment
- Where
- Dorchester, Exeter, Gorleston-on-Sea, Haverfordwest, London, Romford, Shrewsbury, Sutton in Ashfield
- Age
- 16 years and over
- People
- 1,456
- Run by
- University of Birmingham
See details and how to joinNCT07160686 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford
- Age
- 18 years and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - Phase 4Taking peopleA Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy
- Where
- London
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT07761351 - Phase 1/2Taking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- London, Manchester
- Age
- 12 years and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Birmingham, Glasgow, London, Newcastle upon Tyne
- Age
- 18 years and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - Phase 2Taking peopleA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Birmingham, London, Newcastle upon Tyne
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00 - Phase 1/2Taking peopleA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Where
- Edinburgh, London
- Age
- 18 years and over
- People
- 118 worldwide
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933 - No phaseTaking peopleLung cAncer Robotic Comparative Study
- Where
- Bristol, Coventry, London
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT06038227 - Phase 1Taking peopleA Phase 1/1b Study of IAM1363 in HER2 Cancers
- Where
- Chelsea, Oxford, Sutton
- Age
- 18 years and over
- People
- 383 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871 - Phase 1/2Taking peopleInvestigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
- Where
- Manchester, Sutton
- Age
- 18 years and over
- People
- 62
- Run by
- Institute of Cancer Research, United Kingdom
See details and how to joinNCT07718243 - Phase 1Taking peopleA Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
- Where
- London, Manchester
- Age
- 18 years to 75 years
- People
- 9
- Run by
- Zelluna Immunotherapy AS
See details and how to joinNCT07613723 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- London
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 1/2Taking peopleA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Where
- Bristol, Leeds, Liverpool, London, Manchester, Preston
- Age
- 18 years and over
- People
- 594 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01